Trials / Unknown
UnknownNCT04391998
Parasitic Infection in Anemic Pregnant Women
Parasitic Infection in Anemic Pregnant Women. Prevalence and Effects in Rural Area in Egypt.
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Cairo University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
Women included between 18 and 45 years old, pregnant during their second or third trimester of pregnancy (calculated by a sure menstrual date and confirmed by a 1st trimesteric ultrasound) with hemoglobin level below 10.5 mg /dL.
Detailed description
All patients in the study were subjected to: 1. Detailed history was recorded. A proper history concerning age, sex, residence, socioeconomic status, onset, progression, and previous treatment of anemia was taken. Participants' socio-demographic characteristics including gravida and parity were documented, level of education, occupation, Diet, and information useful to determine the socioeconomic level was recorded. Information on previous pregnancies and children and history of chronic diseases were also recorded. 2. General examination; patients were clinically examined and gestational age (assessed by measuring the fundal height), weight was calculated for each participant. 3. Diagnosis of anemia by Complete blood count (CBC), Hb level and measuring hematocrit concentration. 4. Diagnosis of parasitic infection by stool analysis using suitable techniques. 5. Imaging including obstetric ultrasound (U/S) to assess fetal development. 6. Women with helminthic infections will be divided into groups Group (A): received iron + antiparasitic treatment as follows: * Patients who have STH received alzental 200mg tab 2 tabs single oral dose. * Patients who have Entamoeba or Giardia received flagyl 500mg tab twice daily for 5 days. * (B): received iron only.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iron Supplement | oral tablet twice daily after meals |
| DRUG | Metronidazole Oral | 500 mg oral twice daily |
| DRUG | Albendazole | 200 mg oral single dose |
Timeline
- Start date
- 2020-05-13
- Primary completion
- 2021-08-01
- Completion
- 2021-09-01
- First posted
- 2020-05-18
- Last updated
- 2021-02-09
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04391998. Inclusion in this directory is not an endorsement.